Clinical Trial Search

Primary: Percentage of Participants With Parasite Clearance at Day 28 — 97.20 percentage of participants

Primary: Number of Clinical Malaria Episodes Per Year of Follow-up — 0.61; 0.68; 0.64; 0.59 Episodes per PYAR — p=0.8097

Primary: Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a Standardized Approach — 234.5 Ratio

Primary: Cure Rates of AQ-13 and Coartem for Uncomplicated Plasmodium Falciparum Malaria in Adult Malian Males. — 28; 31 Participants

Primary: Emax — 0.201 Maximum clearance rate (1/hour)

Primary: Mean Maximum Temperature — 38.6; 39.2 degrees of Celsius — p=<0.0001

Primary: Incidence and Severity of Observed or Self-reported Adverse Events (AEs) Considered PfSPZ-DVI Challenge Inoculum-related. — 13; 12; 1; 2 Incidence

Primary: Parasitological Success (MITT) — 66; 28; 4; 43 participants — p=<0.005

Primary: Changes in Haemoglobin Concentration From Day 3 Post Treatment of Malaria Episode to Day 90 in the Weekly Chloroquine and Placebo Arms — 93.4; 93.7 g/L

Primary: Derived Parasite Reduction Rate at 24 Hours (PPR24) — 1.38; 1.56; 1.71; 1.63 Log10 parasites/24h — p=0.01

Primary: Percentage of Patients With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28 — 11; 13; 15; 14 Participants

Primary: Number of Participants With Positive Sensitive Blood Smear (sBS) — 0; 0 Participants

Primary: Participants With Local Adverse Events (AEs) - Year One — 3; 1; 0; 0 Participants

Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation of Study Treatment — 13; 6; 5; 3…

Primary: Parasite Clearance Half-life — 1.733; 1.973 Hours — p=>0.05

Primary: Cohort A: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Related TEAEs — 9; 0; 1 Participants

Primary: Infection Rate — 5; 6; 3; 0 Participants

Primary: Change in Haemoglobin Compared to the Baseline — 0.18; 0.54 g/dl

Primary: Crude Cure Rate on Day 14 — 217; 209; 75; 73 Participants

Primary: Number of Participants With Local Adverse Events (AEs) — 0; 1; 1; 1 Participants

Primary: Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Infants and Children (<5 Years) in Post Community…

Primary: 28-day Cure Rate — 63.67 Percentage of participants

Primary: Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled — 61; 88; 90 participants

Primary: Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitologic Response (ACPR) at Day 28 in the Modified Intent-to-treat…

Primary: Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28 — 99.2; 98.1 percentage of subjects — p=0.106

Primary: Emax — 0.35 Maximum clearance rate (1/hour)

Primary: Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants — 6.95; 6.73; 5.21; 3.02 Episode per person year at risk — p=0.57

Primary: P. Vivax Blood Collection — 2 Participants

Primary: Parasitological Success Defined as a Reduction in Parasite Count of ≥ 90% of Baseline at 24 Hours After the First Dose — 14; 10 participants — p=0.17

Primary: Risk of Parasitaemia (Unadjusted by Genotyping) — 23; 87; 164; 147 Participants